Showing 5101-5110 of 9152 results for "".
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- Study: HS Linked to Hyperglycemia and Altered Amino Acid Metabolism in Plasmahttps://practicaldermatology.com/news/study-hs-linked-to-hyperglycemia-and-altered-amino-acid-metabolism-in-plasma/2485657/New research in the Archives of Dermatological Research shows consistent metabolic alterations in patients with moderate-to-severe hidradenitis suppurativa (HS, particiularly regarding energy and amino acid metabolism, that
- REZOLVE-AD: Monthly and Quarterly Dosing of Rezpegaldesleukin Effective for ADhttps://practicaldermatology.com/news/rezolve-ad-monthly-and-quarterly-dosing-of-rezpegaldesleukin-effective-for-ad/2485647/Results from the blinded 36-week maintenance period showed rezpegaldesleukin demonstrated sustained disease control and new or deepening efficacy in moderate-to-severe atopic dermatitis (AD) with both monthly and quarterly dosing regimens, according to an announcem
- Analysis: Agent Orange Exposure Linked to Acral Melanoma Risk in US Veteranshttps://practicaldermatology.com/news/analysis-agent-orange-exposure-linked-to-acral-melanoma-risk-in-us-veterans/2485639/Acral melanoma (AM), a rare melanoma subtype, showed risk factor patterns in a large Veterans Affairs (VA)–based analysis spanning more than two decades, according to new data. In this case-control study of US veterans from 20
- Danish Registry Study Shows Rising cSCC and CIS Incidence Over 18 Yearshttps://practicaldermatology.com/news/nearly-two-decades-of-data-highlight-shifting-patterns-in-keratinocyte-neoplasms/2485635/Incidence rates of cutaneous squamous cell carcinoma (cSCC) and cSCC in situ (CIS) have continued to rise in Denmark over nearly two decades, while keratoacanthoma (KA) incidence has declined, according to a large population-based registry study.
- Fever and Abdominal Purpura Linked to IgAV Recurrence in Adultshttps://practicaldermatology.com/news/fever-and-abdominal-purpura-linked-to-igav-recurrence-in-adults/2485592/Systemic corticosteroids and post-bacterial etiology may protect against recurrence or relapse in adult immunoglobulin A vasculitis (IgAV), a new study suggests. Investigators for the retrospective cohort study
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as
- Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weekshttps://practicaldermatology.com/news/risankizumab-maintains-efficacy-and-safety-in-pediatric-psoriasis-through-52-weeks/2485552/Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented a
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://practicaldermatology.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- 23-Gene Expression Profiling Accurately Classifies Pediatric Melanocytic Lesionshttps://practicaldermatology.com/news/23-gene-expression-profiling-accurately-classifies-pediatric-melanocytic-lesions/2485549/A 23-gene expression profiling assay accurately distinguished benign nevi from melanoma in pediatric patients, according to “23-GEP Accurately Distinguishes Between Melanocytic Nevi and Melanoma in Pediatric Melanocytic Neoplasms,” a poster by Drazen Jukic, MD, et al presented as part of the “Bes